The occurrence and management of fluid retention associated with TKI therapy in CML, with a focus on dasatinib.
about
First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib.New drugs, new toxicities: severe side effects of modern targeted and immunotherapy of cancer and their management.Extensive pleural and pericardial effusion in chronic myeloid leukemia during treatment with dasatinib at 100 mg or 50 mg dailyFluid retention associated with imatinib treatment in patients with gastrointestinal stromal tumor: quantitative radiologic assessment and implications for managementManaging chronic myeloid leukemia patients intolerant to tyrosine kinase inhibitor therapy.Dasatinib - clinical trials and management of adverse events in imatinib resistant/intolerant chronic myeloid leukemiaA critical role for Lyn kinase in strengthening endothelial integrity and barrier function.Optimizing outcomes in patients with chronic myeloid leukemia in chronic phase: comparative safety profiles of newer agents.Management of adverse events associated with tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia.Use of tyrosine kinase inhibitors for chronic myeloid leukemia: management of patients and practical applications for pharmacy practitioners.Linc-DYNC2H1-4 promotes EMT and CSC phenotypes by acting as a sponge of miR-145 in pancreatic cancer cells.Cobll1 is linked to drug resistance and blastic transformation in chronic myeloid leukemia.Simultaneous manifestation of pleural effusion and acute renal failure associated with dasatinib: a case report.Pleural effusion: a rare side effect of nilotinib-a case report.Dasatinib Induced Cardiac Tamponade-A Rare Association.Dasatinib-induced chylothorax in chronic myeloid leukemiaPleural and pericardial effusions in chronic myeloid leukemia patients receiving low-dose dasatinib therapy.Incidence, risk factors and management of pleural effusions during dasatinib treatment in unselected elderly patients with chronic myelogenous leukaemia.Severe dyspnoea in a patient with chronic myelogenous leukaemia on a tyrosine kinase inhibitor.Quality of life outcomes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a controlled comparison.
P2860
Q33392977-5DA9C091-F892-4C6A-929F-23AD66D56FF2Q33564645-DE356B3C-DF34-49BB-A17A-2D851BFE3A17Q34451624-700A9E21-B881-49F4-B342-FC262126E47DQ35140171-AD452F1A-A97E-41C6-A11A-6844EFA2DF3BQ36355098-3761AAB3-E38C-4C27-BC2D-C9C0C01C00EAQ36462473-E8D78ADD-C066-41CA-8932-87F2F7867BE0Q37390244-AA50B70D-DF9D-46AB-B4E8-5660DA1D45C3Q37763106-BED11D2F-9449-4F01-8C43-9D725562620AQ37791429-023B13C5-3252-44FC-86A3-77ABC6A59EFDQ37889508-4CC0FF41-1260-42AE-890F-7F0AFAEB0699Q38697454-B8F39FBB-7B7E-4D2F-AAA2-436D98E5005FQ38715100-01F22A0E-7577-4BC4-8F2D-0E59C5EDC77CQ40229471-331BEBA9-5CED-4978-A901-2B04C8864DECQ41809416-F1195D54-1298-4BD5-8591-86B537F1AD79Q42293055-4FF17037-C931-417F-8052-636FC611692DQ42330001-902F3830-0619-46C4-AC80-9A2D4169BE0EQ42639060-A899A9AB-E70D-4743-85AA-8C37493AD370Q44129015-9DF6E050-8D00-4A40-8027-26BE878635F0Q47975878-B7EEF08F-050C-4CEE-871B-C222D4BD30ECQ48210350-343C8D55-9E79-46A3-BFF5-1F0C265891E8
P2860
The occurrence and management of fluid retention associated with TKI therapy in CML, with a focus on dasatinib.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh
2009年學術文章
@zh-hant
name
The occurrence and management ...... ML, with a focus on dasatinib.
@en
The occurrence and management ...... ML, with a focus on dasatinib.
@nl
type
label
The occurrence and management ...... ML, with a focus on dasatinib.
@en
The occurrence and management ...... ML, with a focus on dasatinib.
@nl
prefLabel
The occurrence and management ...... ML, with a focus on dasatinib.
@en
The occurrence and management ...... ML, with a focus on dasatinib.
@nl
P2093
P2860
P921
P356
P1476
The occurrence and management ...... ML, with a focus on dasatinib.
@en
P2093
Allen S Yang
David Masiello
Gerry Gorospe
P2860
P2888
P356
10.1186/1756-8722-2-46
P5008
P577
2009-11-12T00:00:00Z
P5875
P6179
1008469046